Results 91 to 100 of about 26,505 (287)
Diabetic Medicine, EarlyView.Abstract Background Although ethnic disparities in diabetes prevalence and chronic complications are well recognised, their association with acute metabolic emergencies and outcomes is not well established. In this study, we investigated the association between ethnicity and clinical outcomes.
Aspasia Manta +40 more
wiley +1 more source
, 1991 Available from British Library Document Supply Centre- DSC:q91/15871(Sulfonylurea) / BLDSC - British Library Document Supply CentreSIGLEGBUnited ...
Smith, C +1 more
core
, 2020 Background: Due to several limitations in the study designs of sulfonylurea pharmacogenomics studies, we investigated the clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients.
Vethakkan, Shireene Ratna +3 more
core
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe +13 more
wiley +1 more source
Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristics [PDF]
, 1994 Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with ...
Kramer, Werner +9 more
core +1 more source
Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi +7 more
wiley +1 more source
Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications
Nigerian Journal of Medicine, 2017 INTRODUCTION: We sought to explore the current state of evidence on sulfonylurea therapy in type 2 diabetes mellitus (T2DM) and critically examine the recommendations of major practice guidelines,and the overall ramifications of the issues thereof in ...
Chiedozie Kenneth Ugwoke +3 more
doaj +1 more source
Stimulation of a glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonylurea, glimepiride, in rat adipocytes depends on increased glucose transport [PDF]
, 1994 Korndörfer, Andrea +7 more
core +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran +3 more
wiley +1 more source